Ovarian Cancer accounted for a 4.6% share of the global clinical trials within the Oncology therapy area in 2021, registering an increase of 0.1% when compared with the last ten-year average of 4.5% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for Ovarian Cancer
Industry sponsored trials held a 56.9% share of all the clinical trials for Ovarian Cancer indication in 2021, registering an increase of 6.9% when compared with the ten-year average of 50.0%. Non-industry sponsored trials accounted for a 43.1% share in 2021, marking a decrease of 6.9% over the ten-year average of 50.0%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Ovarian Cancer trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataNorth America was the top region for industry sponsored Ovarian Cancer trials, accounting for a 52.3% share in 2021, when compared with the five-year average of 66.3% and ten-year average of 67.1%.
Asia-Pacific was at the second position with a 48.3% share in 2021, over the five-year average of 45.3% and ten-year average of 35.7%, followed by Europe with a 29.5% share in 2021, as against five-year and ten-year averages of 37.9% and 43.1% respectively.
Middle East and Africa stood fourth with a 4.7% share in 2021, compared with the five-year average of 5.5% and ten-year average of 5.3%, followed by South and Central America with a 3.4% share in 2021, over five-year and ten-year averages of 4.2% and 4.2% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Ovarian Cancer trials, accounting for a 51.0% share in 2021, as against the five-year average of 65.6% and ten-year average of 66.0%.
China held a 30.9% share in 2021, over the five-year average of 16.2% and ten-year average of 10.5%, followed by UK with a 14.8% share in 2021, compared with the five-year and ten-year averages of 18.8% and 19.7% respectively.
Spain held an 11.4% share in 2021, as against the five-year average of 19.7% and ten-year average of 20.6%.
Canada held an 11.4% share in 2021, over the five-year and ten-year averages of 15.5% and 16.8% respectively.
Top regions of non-industry sponsored Ovarian Cancer trials
Asia-Pacific was the top region for non-industry sponsored Ovarian Cancer trials, accounting for a 48.4% share in 2021 when compared with the five-year average of 42.9% and ten-year average of 35.9%.
North America was at the second position with a 34.4% share in 2021, over the five-year and ten-year averages of 35.1% and 40.8% respectively, followed by Europe with a 16.4% share in 2021, as against the five-year average of 24.0% and ten-year average of 26.7%.
Middle East and Africa stood at the fourth position with a 0.8% share in 2021, compared with the five-year average of 2.3% and ten-year average of 1.4%, followed by South and Central America with a 0.0% share in 2021, over the five-year and ten-year averages of 1.1% and 1.0% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Ovarian Cancer trials, accounting for a 40.2% share in 2021, as against the five-year average of 29.6% and ten-year average of 17.7%.
The US held a 31.1% share in 2021, over the five-year average of 31.5% and ten-year average of 37.7%, followed by Canada with a 4.1% share, compared with the five-year and ten-year averages of 4.1% and 4.3% respectively.
France held a 4.1% share in 2021, as against the five-year average of 6.3% and ten-year average of 6.6%.
South Korea held a 3.3% share in 2021, over the five-year average of 4.1% and ten-year average of 3.8%.
Phase I trials lead industry sponsored clinical trials for Ovarian Cancer in 2021
Phase I trials held a 49.4% share of industry sponsored clinical trials for Ovarian Cancer in 2021, over the five-year average of 48.8% and ten-year average of 50.5%.
Phase II trials held a 39.3% share in 2021, as against the five-year average of 41.4% and ten-year average of 37.8%. Phase III trials held a 6.5% share in 2021, compared with the five-year and ten-year averages of 7.0% and 7.0% respectively.
Phase IV trials held a 4.8% share in 2021, over the five-year average of 2.7% and ten-year average of 4.6%.
Phase II trials lead non-industry sponsored clinical trials for Ovarian Cancer in 2021
Phase II trials held a 52.0% share of non-industry sponsored clinical trials for Ovarian Cancer in 2021, over the five-year average of 56.1% and ten-year average of 56.2%.
Phase I trials held a 29.9% share in 2021, as against the five-year average of 21.9% and ten-year average of 25.4%. Phase IV trials held an 11.8% share, compared with the five-year and ten-year averages of 12.7% and 9.4% respectively.
Phase III trials held a 6.3% share in 2021, over the five-year average of 9.3% and ten-year average of 9.0%.
Methodology: The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
